CN102892777B - 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物 - Google Patents

用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物 Download PDF

Info

Publication number
CN102892777B
CN102892777B CN201180014643.6A CN201180014643A CN102892777B CN 102892777 B CN102892777 B CN 102892777B CN 201180014643 A CN201180014643 A CN 201180014643A CN 102892777 B CN102892777 B CN 102892777B
Authority
CN
China
Prior art keywords
cancer
peptide
cells
peptides
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180014643.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102892777A (zh
Inventor
延斯·弗里切
托尼·怀申克
斯特芬·沃尔特
彼得·莱维卓尔斯奇
哈普利特·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of CN102892777A publication Critical patent/CN102892777A/zh
Application granted granted Critical
Publication of CN102892777B publication Critical patent/CN102892777B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
CN201180014643.6A 2010-03-19 2011-03-16 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物 Expired - Fee Related CN102892777B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31571510P 2010-03-19 2010-03-19
GB201004575A GB201004575D0 (en) 2010-03-19 2010-03-19 Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US61/315,715 2010-03-19
GB1004575.5 2010-03-19
PCT/EP2011/053996 WO2011113872A1 (en) 2010-03-19 2011-03-16 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Publications (2)

Publication Number Publication Date
CN102892777A CN102892777A (zh) 2013-01-23
CN102892777B true CN102892777B (zh) 2017-02-08

Family

ID=42227968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180014643.6A Expired - Fee Related CN102892777B (zh) 2010-03-19 2011-03-16 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物

Country Status (21)

Country Link
US (2) US10159725B2 (enExample)
EP (1) EP2547691B1 (enExample)
JP (1) JP5689140B2 (enExample)
KR (1) KR101620132B1 (enExample)
CN (1) CN102892777B (enExample)
AU (1) AU2011229177B2 (enExample)
BR (1) BR112012023621A2 (enExample)
CA (1) CA2793389A1 (enExample)
EA (1) EA022743B1 (enExample)
ES (1) ES2593409T3 (enExample)
GB (1) GB201004575D0 (enExample)
HU (1) HUE030000T2 (enExample)
MX (1) MX2012010814A (enExample)
MY (1) MY162850A (enExample)
NZ (1) NZ601818A (enExample)
PH (1) PH12012501822A1 (enExample)
PL (1) PL2547691T3 (enExample)
SG (1) SG183938A1 (enExample)
TW (1) TWI533882B (enExample)
UA (1) UA109891C2 (enExample)
WO (1) WO2011113872A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP3855184B1 (en) * 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
CN103961307B (zh) * 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
US10507235B2 (en) * 2013-03-19 2019-12-17 Globeimmune, Inc. Yeast-based immunotherapy for Chordoma
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
CA2955456A1 (en) * 2014-07-17 2016-01-21 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
PT3319985T (pt) * 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN116375797A (zh) * 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
WO2017170365A1 (ja) * 2016-03-28 2017-10-05 東レ株式会社 免疫誘導剤
CA3059210C (en) * 2016-05-19 2022-07-19 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018046468A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag Mhc-bound peptide arrays and methods of use thereof
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
SG11201907524UA (en) * 2017-03-03 2019-09-27 Treos Bio Zrt Peptide vaccines
CN110662556A (zh) * 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11911451B2 (en) * 2017-08-22 2024-02-27 ImmuLogix Ltd Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
FI3773689T3 (fi) * 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220218822A1 (en) * 2019-05-02 2022-07-14 SURGE Therapeutics, Inc. Cancer treatment
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021155501A1 (zh) * 2020-02-05 2021-08-12 瓦克斯恩有限公司 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN115181186B (zh) * 2021-09-24 2025-04-18 武汉百英诺科技合伙企业(有限合伙) 一种抑制肿瘤侵袭转移的多肽组合及其应用
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CN101287755A (zh) * 2005-09-05 2008-10-15 伊玛提克斯生物技术有限公司 结合于人类白细胞抗原(hla)ⅰ类或ⅱ类分子的肿瘤相关肽及相关的抗癌疫苗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1117430A1 (en) 1998-10-05 2001-07-25 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
US20040072753A1 (en) 2000-11-01 2004-04-15 Milton Nathaniel Gavin Nicolas Peptides for use in the treatment of alzheimer's disease
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ES2319286T3 (es) 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
WO2007005635A2 (en) 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
HUE027057T2 (en) * 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
PL2113253T3 (pl) * 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
HUE024541T2 (hu) * 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CN101287755A (zh) * 2005-09-05 2008-10-15 伊玛提克斯生物技术有限公司 结合于人类白细胞抗原(hla)ⅰ类或ⅱ类分子的肿瘤相关肽及相关的抗癌疫苗

Also Published As

Publication number Publication date
US20110229524A1 (en) 2011-09-22
EA022743B1 (ru) 2016-02-29
TWI533882B (zh) 2016-05-21
JP5689140B2 (ja) 2015-03-25
US10159725B2 (en) 2018-12-25
HUE030000T2 (en) 2017-04-28
AU2011229177B2 (en) 2014-09-25
PL2547691T3 (pl) 2016-12-30
JP2013522276A (ja) 2013-06-13
AU2011229177A1 (en) 2012-09-06
MY162850A (en) 2017-07-31
KR20130057428A (ko) 2013-05-31
EP2547691B1 (en) 2016-06-29
MX2012010814A (es) 2012-11-12
KR101620132B1 (ko) 2016-05-12
NZ601818A (en) 2014-09-26
UA109891C2 (uk) 2015-10-26
TW201201834A (en) 2012-01-16
CN102892777A (zh) 2013-01-23
EA201201305A1 (ru) 2013-02-28
PH12012501822A1 (en) 2019-07-10
GB201004575D0 (en) 2010-05-05
BR112012023621A2 (pt) 2017-07-18
EP2547691A1 (en) 2013-01-23
WO2011113872A1 (en) 2011-09-22
US9132177B2 (en) 2015-09-15
ES2593409T3 (es) 2016-12-09
CA2793389A1 (en) 2011-09-22
US20130115188A1 (en) 2013-05-09
SG183938A1 (en) 2012-10-30
HK1180701A1 (zh) 2013-10-25

Similar Documents

Publication Publication Date Title
CN102892777B (zh) 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物
KR101687840B1 (ko) 아교모세포종(ｇｂｍ) 및 다른 암의 치료를 위한 종양-관련 펩티드 및 관련된 항암 백신의 조성물
US7994276B2 (en) Composition of tumour-associated peptides and related anti-cancer vaccine
US9023802B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9023804B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN103547283A (zh) 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
TW201209410A (en) Methods for the diagnosis and treatment of cancer based on AVL9
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
HK1180701B (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170208

Termination date: 20180316

CF01 Termination of patent right due to non-payment of annual fee